Vaccine candidate was well-tolerated with no vaccine-related serious adverse events Highest immune responses observed with a single dose of vaccine combined with aluminum phosphate adjuvant Women with the lowest baseline levels of RSV neutralizing antibodies had the largest increases following immunization, consistent with prior data Palivizumab-like antibodies exceeded levels observed in previous trials High levels of antibodies developed within 14 days after …